TM7SF2 Antibody

What is TM7SF2 and why is it of interest to researchers?

TM7SF2 (Transmembrane 7 Superfamily Member 2) is a protein that has gained significant research interest due to its dual roles: as a nuclear membrane protein that influences genome organization and as an enzyme involved in sterol reduction pathways. Recent research has identified TM7SF2 as a potential biomarker in colorectal cancer, with its expression correlating with disease progression and patient survival rates . Additionally, TM7SF2 has been implicated in tissue-specific patterns of genome organization, making it relevant to studies in epigenetics and nuclear architecture . As a paralog of the HP1-binding nuclear membrane protein LBR, TM7SF2 represents an important target for researchers investigating nuclear envelope proteins and their functional roles.

What are the common applications for TM7SF2 antibodies in research?

TM7SF2 antibodies are commonly utilized in several experimental applications including:

• Western blotting for protein expression analysis and quantification

• Immunohistochemistry (IHC) for tissue localization studies, particularly in cancer research

• Immunofluorescence (IF) for subcellular localization studies, especially for examining nuclear membrane positioning

• ELISA-based assays for quantitative protein detection

These applications enable researchers to investigate TM7SF2 expression patterns, subcellular localization, and potential associations with disease states or cellular processes. When selecting a TM7SF2 antibody, it is essential to consider the specific application requirements and validate the antibody accordingly before proceeding with key experiments.

What species reactivity should be considered when selecting a TM7SF2 antibody?

When selecting a TM7SF2 antibody, species reactivity is a critical consideration that depends on your experimental model. Available TM7SF2 antibodies demonstrate varying reactivity profiles, with many showing high sequence conservation across species. Current commercially available antibodies show reactivity with human, mouse, rat, cow, dog, guinea pig, horse, rabbit, monkey, and pig TM7SF2 . Sequence analysis by BLAST reveals 100% identity in many mammalian species including human, dog, bovine, rabbit, horse, and pig, with slightly lower identity (92%) in species like goat . For cross-species studies, it is advisable to select antibodies targeting highly conserved epitopes in the TM7SF2 sequence, such as those in the range of amino acids 35-84, which show strong conservation across multiple species .

How should researchers validate TM7SF2 antibodies for specific applications?

Proper validation of TM7SF2 antibodies is essential for generating reliable research data. A comprehensive validation approach should include:

• Positive and negative controls: Include lysates or samples from cells with known TM7SF2 expression levels. For negative controls, consider using TM7SF2 knockdown models generated via siRNA, as demonstrated in colorectal cancer cell lines (SW480 and SW620) .

• Antibody specificity tests: Perform pre-absorption tests with the immunogenic peptide, particularly for polyclonal antibodies targeting specific epitopes (such as AA 35-84) .

• Cross-validation with multiple detection methods: Compare results from different techniques (e.g., western blot, IHC, and IF) to confirm consistent detection patterns.

• Molecular weight verification: TM7SF2 should display appropriate molecular weight on western blots; inconsistencies may indicate non-specific binding or post-translational modifications.

• Genetic models: When possible, utilize TM7SF2 knockout models (like the Tm7sf2−/− mouse model) to validate antibody specificity, as any signal in knockout tissues would indicate non-specific binding .

What protein extraction methods are optimal for TM7SF2 detection in western blotting?

TM7SF2 is a transmembrane protein localized to the nuclear envelope and endoplasmic reticulum, necessitating specialized extraction protocols:

• Membrane protein extraction: Use dedicated membrane protein extraction buffers containing non-ionic detergents (e.g., Triton X-100 or NP-40) to effectively solubilize TM7SF2 from membranes.

• Nuclear fraction enrichment: For studies focusing on nuclear envelope localization, employ nuclear fractionation protocols to enrich for nuclear membrane proteins.

• Denaturation conditions: Complete denaturation with SDS and reducing agents is crucial for proper resolution of this multi-pass transmembrane protein.

• Sample handling: Maintain samples at appropriate temperatures to prevent protein degradation; avoid excessive freeze-thaw cycles.

• Protease inhibitors: Always include a comprehensive protease inhibitor cocktail in extraction buffers to prevent degradation of TM7SF2 during sample preparation.

When detecting TM7SF2 in colorectal cancer cells like SW480 and SW620, researchers have successfully used standard protein extraction protocols followed by western blotting to detect both endogenous expression and siRNA-mediated knockdown .

How can TM7SF2 antibodies be utilized to study its role as a cancer biomarker?

Recent research has identified TM7SF2 as a potential biomarker in colorectal cancer with significant clinical implications . To investigate TM7SF2's biomarker potential, researchers can employ the following methodological approaches:

• Tissue microarray analysis: Perform immunohistochemistry using validated TM7SF2 antibodies on tissue microarrays containing samples from different cancer stages and normal tissues. Quantitative scoring systems can then be applied to correlate expression levels with clinicopathological features and patient outcomes .

• Survival analysis correlation: Use Kaplan-Meier survival analysis to evaluate the relationship between TM7SF2 expression levels (as determined by antibody staining intensity) and patient survival rates. In colorectal cancer, for example, high TM7SF2 expression correlates with decreased 5-year survival rates (approximately 4.2% versus 14% for low expression) .

• Multivariate analysis: Perform Cox regression analysis to determine whether TM7SF2 expression represents an independent prognostic factor when accounting for other clinical variables.

• Metastasis correlation studies: Compare TM7SF2 expression between primary tumors and metastatic tissues using paired samples to investigate its potential role in metastatic progression. This approach has been successfully applied using primary and metastatic colorectal cancer cell lines (SW480 and SW620) .

• Functional validation: Following identification of TM7SF2 as a potential biomarker, validate its functional relevance through knockdown experiments and subsequent functional assays examining proliferation, migration, invasion, and colony formation .

What experimental approaches can be used to investigate TM7SF2's role in gene positioning and nuclear organization?

TM7SF2 has been identified as a nuclear envelope protein that contributes to tissue-specific patterns of radial genome organization . To study this role, researchers can employ these specialized approaches:

• DamID technology: Utilize Dam-LaminB1 global profiling in primary cells from wild-type and Tm7sf2−/− models to identify genes whose nuclear positioning is affected by TM7SF2 absence. This technique involves fusion of DNA adenine methyltransferase (Dam) to LaminB1, allowing identification of genome regions that interact with the nuclear lamina .

• Lentiviral expression systems: For rescue experiments, use lentiviral vectors expressing TM7SF2-EGFP fusion proteins to reintroduce the protein into knockout models and assess restoration of normal gene positioning patterns .

• Point mutation studies: Generate TM7SF2 constructs with specific point mutations (based on C14SR homolog studies) to investigate which protein domains are critical for its nuclear organization functions versus its enzymatic functions .

• Primary cell isolation and culture: For physiologically relevant results, isolate primary hepatocytes using collagenase perfusion methods rather than relying solely on immortalized cell lines. This approach better recapitulates the tissue-specific aspects of TM7SF2 function .

• Fluorescence in situ hybridization (FISH): Use FISH to directly visualize the positioning of specific genes relative to the nuclear periphery in wild-type versus Tm7sf2−/− cells.

How can researchers distinguish between TM7SF2's dual roles in sterol metabolism and nuclear organization?

TM7SF2 presents an interesting case of a protein with dual functionality: it acts both as a nuclear envelope protein influencing genome organization and as an enzyme involved in sterol reduction pathways . To dissect these distinct functions:

• Structure-function analysis: Generate point mutations in the enzymatic domain of TM7SF2 that disrupt its sterol reductase activity without affecting its protein-protein interactions. Conversely, create mutations that disrupt its nuclear envelope interactions while preserving enzymatic function .

• Complementation experiments: In Tm7sf2−/− models, perform rescue experiments with different mutant versions of the protein to determine which functions can be restored by which protein domains.

• Metabolomic profiling: Combine TM7SF2 antibody-based expression studies with lipidomic/metabolomic analyses to correlate changes in sterol metabolism with alterations in gene positioning and expression.

• Comparative studies with LBR: As TM7SF2 is a paralog of LBR (which also has dual functions in genome organization and sterol reduction), comparative studies between these proteins can help elucidate their specialized roles .

• Transcriptomic analysis: Perform RNA-seq in wild-type versus Tm7sf2−/− tissues to identify genes whose expression changes when TM7SF2 is absent, then categorize these based on pathways related to either nuclear organization or sterol metabolism.

What are the common technical challenges when using TM7SF2 antibodies in immunohistochemistry?

Immunohistochemical detection of TM7SF2 can present several technical challenges that researchers should anticipate and address:

• Optimization of antigen retrieval: As a transmembrane protein, TM7SF2 may require specialized antigen retrieval methods to expose epitopes embedded in membrane structures. Compare heat-induced epitope retrieval (HIER) methods using citrate buffer (pH 6.0) versus EDTA buffer (pH 9.0) to determine optimal conditions.

• Fixation considerations: Overfixation can mask TM7SF2 epitopes, particularly in formalin-fixed, paraffin-embedded tissues. Carefully control fixation time and consider testing antibodies on frozen sections if persistent detection issues occur.

• Background reduction: When using polyclonal TM7SF2 antibodies, non-specific background staining may occur. Implement additional blocking steps using 5% normal serum from the same species as the secondary antibody and consider adding 0.1-0.3% Triton X-100 for improved antibody penetration.

• Signal amplification: For tissues with low TM7SF2 expression, signal amplification systems such as tyramide signal amplification may be necessary while ensuring that controls are used to distinguish true signal from amplified background.

• Subcellular localization interpretation: TM7SF2 exhibits strong expression in both the plasma membrane and cytoplasm of colorectal cancer tissues . Be aware of this dual localization pattern when scoring and interpreting IHC results.

How can researchers accurately quantify TM7SF2 expression levels for comparative studies?

Accurate quantification of TM7SF2 expression is essential for comparative studies, particularly when investigating its potential as a biomarker:

• Standardized scoring systems: For IHC analyses, implement standardized scoring systems that account for both staining intensity and percentage of positive cells. In colorectal cancer studies, a scoring system that classifies expression as "high" or "low" based on established cutoff values has proven effective for survival correlations .

• Digital image analysis: Employ quantitative digital image analysis software to obtain objective measurements of staining intensity and reduce inter-observer variability.

• Internal controls: Include internal control tissues with known TM7SF2 expression levels in each experimental batch to normalize for staining variability between experiments.

• Multiple antibody validation: Confirm expression patterns using multiple antibodies targeting different epitopes of TM7SF2 to ensure consistent quantification.

• Combination with other methods: Validate IHC-based expression data with orthogonal methods such as RT-PCR and western blotting. In knockdown experiments, for example, researchers have demonstrated that TM7SF2 siRNA can reduce mRNA levels by 75-90% and protein levels by 62-78% .

How might TM7SF2 antibodies be utilized in developing targeted therapies for colorectal cancer?

Based on recent findings implicating TM7SF2 in colorectal cancer progression and metastasis , several research avenues could employ TM7SF2 antibodies in therapeutic development:

• Antibody-drug conjugates (ADCs): Develop and test ADCs targeting TM7SF2 to deliver cytotoxic payloads specifically to cancer cells with high TM7SF2 expression.

• Prognostic companion diagnostics: Standardize TM7SF2 antibody-based IHC assays as companion diagnostics to identify patients more likely to benefit from therapies targeting pathways affected by TM7SF2.

• Mechanism exploration: Use TM7SF2 antibodies to investigate the C-Raf/ERK1/2 pathway in colorectal cancer, as TM7SF2 suppression has been shown to inhibit this pathway in cervical cancer . Understanding the signaling mechanisms could reveal additional therapeutic targets.

• Combination therapy biomarkers: Investigate whether TM7SF2 expression levels correlate with response to existing therapies, potentially guiding combination treatment strategies.

• Functional antibodies: Explore whether antibodies targeting external domains of TM7SF2 could have direct functional effects by interfering with its activity or interactions, potentially inhibiting cancer progression.

What innovative techniques are emerging for studying TM7SF2's role in nuclear architecture and gene regulation?

Emerging technologies offer new possibilities for investigating TM7SF2's role in nuclear organization:

• Single-cell genomics combined with immunolabeling: Integrate single-cell RNA-seq with TM7SF2 antibody-based cell sorting to correlate expression levels with transcriptional profiles at single-cell resolution.

• CUT&RUN and CUT&Tag technologies: Apply these techniques with TM7SF2 antibodies to map TM7SF2-associated chromatin regions with higher resolution than traditional ChIP-seq approaches.

• Live-cell imaging with antibody fragments: Develop Fab fragments of TM7SF2 antibodies conjugated to fluorophores for live-cell imaging of TM7SF2 dynamics without disrupting its function.

• Proximity labeling techniques: Employ BioID or APEX2 fusion proteins with TM7SF2 to identify its protein interaction network at the nuclear envelope, providing insights into its gene regulatory mechanisms.

• Chromatin conformation capture technologies: Combine Hi-C or related techniques with TM7SF2 manipulation to examine how this protein influences 3D genome organization and chromatin compartmentalization in relation to gene expression patterns.